A5009874188- Ocular Surface and Contact Lens
- Glaucoma and retinal disorders
- Corneal surgery and disorders
- Corneal Surgery and Treatments
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Ocular Infections and Treatments
- Intraocular Surgery and Lenses
- Allergic Rhinitis and Sensitization
- Ophthalmology and Visual Impairment Studies
- Olfactory and Sensory Function Studies
- Ophthalmology and Eye Disorders
- Laser Applications in Dentistry and Medicine
- Artificial Intelligence in Healthcare and Education
- Retinal and Macular Surgery
- Ocular Diseases and Behçet’s Syndrome
- Facial Rejuvenation and Surgery Techniques
- Advancements in Transdermal Drug Delivery
- Dermatologic Treatments and Research
- Dermatology and Skin Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Cerebral Venous Sinus Thrombosis
- Advanced Glycation End Products research
- Ocular Oncology and Treatments
University of Cagliari
2023-2025
Magna Graecia University
2019-2024
Ophthalmology Associates (United States)
2024
Policlinico S.Orsola-Malpighi
2012-2023
University of Bologna
2014-2023
University of Messina
2023
Sapienza University of Rome
2021
L.Garde (United States)
2021
Ospedale Policlinico San Martino
2019-2020
University of Genoa
2020
To compare the performance of humans, GPT-4.0 and GPT-3.5 in answering multiple-choice questions from American Academy Ophthalmology (AAO) Basic Clinical Science Course (BCSC) self-assessment program, available at https://www.aao.org/education/self-assessments . In June 2023, text-based were submitted to GPT-3.5. The AAO provides percentage humans who selected correct answer, which was analyzed for comparison. All classified by 10 subspecialties 3 practice areas (diagnostics/clinics, medical...
Abstract Purpose To assess clinical results of the 9 mW/5.4 J/cm 2 accelerated crosslinking (ACXL) in treatment progressive keratoconus (KC) over a span 5 years. Methods The prospective open non-randomized interventional study (Siena Eye-Cross Study 2) included 156 eyes 112 patients with early KC undergoing Epi-Off ACXL at Siena Crosslinking Centre, Italy. mean age was 18.05 ± 5.6 20-min treatments were performed using New KXL I (Avedro, Waltham, USA), 10 min 0.1% HPMC Riboflavin soaking...
This quality improvement study evaluates the ability of GPT-4 Advanced Data Analysis to create a fake data set that can be used for purpose scientific research.
Dry eye disease (DED) incidence is continuously growing, positioning it to become an emergent health issue over the next few years. Several topical treatments are commonly used treat DED; however, reports indicate that only a minor proportion of drug bioavailability achieved by majority drops available on market. In this context, enhancing ability overcome ocular barriers and prolonging its residence time surface represent new challenge in field carrier systems. Therefore, research has...
Background and Objectives: Age-related macular degeneration (AMD) remains a leading cause of legal blindness. Anti-Vascular Endothelial Growth Factor (VEGF) agents are the first-line treatment for neovascular AMD (nAMD). The choroid plays key role in is affected by anti-VEGF treatment. Faricimab, bispecific antibody additionally targeting angiopoietin 2 (Ang2), was recently approved nAMD This study investigates effect Faricimab on choroidal flow signal. Materials Methods: Optical coherence...